文献速递神经免疫

多发性硬化患者接受那他珠单抗治疗后进行性多灶性白质脑病病灶体积与脑脊液JC病毒聚合酶链反应结果的关联

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项回顾性横断面研究纳入56例那他珠单抗相关进行性多灶性白质脑病(NTZ-PML)的多发性硬化患者,分析脑MRI病灶特征与脑脊液JC病毒PCR结果的关系。发现脑脊液JC病毒DNA阳性者PML病灶体积大于检测不到者,病灶体积越小越可能检测不到JC病毒DNA。

要点

  • 56例NTZ-PML患者中9例(16.1%)脑脊液JC病毒DNA检测不到。
  • PCR阳性者PML病灶体积大于DNA检测不到者(中位22.9 mL vs 6.7 mL,P=0.008)。
  • PML病灶体积与JC病毒拷贝数呈正相关(Spearman ρ=0.32,P=0.03)。

核心结论

  • 较小的NTZ-PML病灶与脑脊液JC病毒DNA检测不到的可能性更高相关,这可能妨碍PML的正式诊断。

研究设计与样本

  • 回顾性横断面研究,纳入2007年1月至2014年12月荷兰-比利时NTZ-PML队列及比利时和荷兰多家医疗中心选出的患者,随访至少6个月,筛查73例后纳入56例(37例女性)。

主要发现

  • 入组时56例中9例(16.1%)脑脊液JC病毒DNA检测不到。
  • PCR阳性者总PML病灶体积中位22.9 mL(四分位距9.2-60.4 mL),大于DNA检测不到者的中位6.7 mL(四分位距4.9-14.7 mL),P=0.008。
  • 逻辑回归显示较低的PML病灶体积显著增加JC病毒DNA检测不到的概率。
  • PML病灶体积与JC病毒拷贝数呈正相关(Spearman ρ=0.32,P=0.03)。
  • 有PML症状者及病灶播散更广泛者PML病灶体积更高;PCR结果与PML病灶播散、炎症征象或PML症状无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The JC virus (JCV) was named after the first patient to be described with progressive multifocal leukoencephalopathy (PML), John Cunningham. Detection of JC virus DNA in cerebrospinal fluid (CSF) by polymerase chain reaction (PCR), and of specific lesions by brain magnetic resonance imaging (MRI), are both considered essential for the diagnosis of natalizumab-associated PML (NTZ-PML) in patients with multiple sclerosis. However, strict pharmacovigilance by MRI can result in detection of patients with small lesions and undetectable JCV DNA in CSF. OBJECTIVE: To investigate the association of PML lesion characteristics on MRI with both qualitative and quantitative JCV PCR results in CSF of patients with NTZ-PML. DESIGN, SETTING AND PARTICIPANTS: This was a retrospective, cross-sectional study conducted from January 2007 to December 2014 in patients considered to have NTZ-PML based on a set of predefined criteria. Follow-up was at least 6 months. Data of patients from the Dutch-Belgian NTZ-PML cohort and patients treated at multiple medical centers in Belgium and the Netherlands and selected for research purposes were included as a convenience sample. MAIN OUTCOMES AND MEASURES: Brain MRI scans were analyzed for PML lesion volume, location, dissemination, and signs of inflammation. Associations of the qualitative and quantitative CSF JCV PCR results with PML MRI characteristics were calculated. RESULTS: Of the 73 patients screened, 56 were included (37 were women). At inclusion, 9 patients (16.1%) had undetectable JCV DNA in CSF. Patients with a positive PCR had larger total PML lesion volumes than those with undetectable JCV DNA (median volume, 22.9 mL; interquartile range, 9.2-60.4 mL vs median volume, 6.7 mL; interquartile range, 4.9-14.7 mL; P = .008), and logistic regression showed that a lower PML lesion volume significantly increased the probability for undetectable JCV DNA. There was a positive correlation between PML lesion volume and JCV copy numbers (Spearman ρ, 0.32; P = .03). Progressive multifocal leukoencephalopathy lesion volume was higher in patients with PML symptoms and in patients with more widespread lesion dissemination. No association was found between PCR results and PML lesion dissemination, signs of inflammation, or PML symptoms. CONCLUSIONS AND RELEVANCE: Smaller NTZ-PML lesions are associated with a higher likelihood of undetectable JCV DNA in CSF. This may preclude a formal diagnosis of PML and can complicate patient treatment in patients with small MRI lesions highly suggestive of PML detected early through pharmacovigilance.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. JAMA Neurol. 2018. PMID: 29532061. doi:10.1001/jamaneurol.2018.0094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。